Under the influence of declining birth rates, expanding longevity, and changing population structures around the world, the global prevalence of senile dementia is expected to increase more than four-fold within the next forty years. Within the United States alone, the number of affected individuals over the age of 65 is expected to rise exponentially from 8 million cases (2% of the entire population in the year 2000), to 18 million retirees (roughly 4.5% of the national census in the year 2040). Although they are striking, these statistics quite likely underestimate the scope of the coming epidemic, as they fail to consider the impact of under-diagnosis, early-onset disease, and the potential for a changing incidence of illness in the context of increasingly toxic environments. In the face of this imminent crisis, concerned observers have called for policies and practices which aim to prevent, limit, or reverse dementia. Drug-Induced Dementia: A Perfect Crime is a timely resource which reveals why and how medical treatments themselves - specifically, psychopharmaceuticals - are a substantial cause of brain degeneration and premature death. A first-of-its-kind resource for patients and clinicians, the book integrates research findings from epidemiology (observational studies of patients in the "real world"), basic biology (animal experiments), and clinical science (neuroimaging and autopsy studies) in order to demonstrate the dementing and deadly effects of psychiatric drugs. Highlighted by more than 100 neuroimages, slides of tissue specimens, and illustrations, the book uniquely describes: the societal roots of the problem (target organ toxicity, regulatory incompetence, and performativity) the subtypes and essential causes of dementia the patterns, prevalence, and causes of dementia associated with antidepressants, antipsychotics, anxiolytics, mood stabilizers, and stimulants and the actions and reforms which patients, providers, and policy makers might immediately pursue, in an effort to mitigate the causes and consequences of this iatrogenic tragedy.

Under the influence of declining birth rates, expanding longevity, and changing population structures around the world, the global prevalence of senile dementia is expected to increase more than four-fold within the next forty years. Within the United States alone, the number of affected individuals over the age of 65 is expected to rise exponentially from 8 million cases (2% of the entire population in the year 2000), to 18 million retirees (roughly 4.5% of the national census in the year 2040). Although they are striking, these statistics quite likely underestimate the scope of the coming epidemic, as they fail to consider the impact of under-diagnosis, early-onset disease, and the potential for a changing incidence of illness in the context of increasingly toxic environments. In the face of this imminent crisis, concerned observers have called for policies and practices which aim to prevent, limit, or reverse dementia. Drug-Induced Dementia: A Perfect Crime is a timely resource which reveals why and how medical treatments themselves – specifically, psychopharmaceuticals – are a substantial cause of brain degeneration and premature death. A first-of-its-kind resource for patients and clinicians, the book integrates research findings from epidemiology (observational studies of patients in the "real world"), basic biology (animal experiments), and clinical science (neuroimaging and autopsy studies) in order to demonstrate the dementing and deadly effects of psychiatric drugs. Highlighted by more than 100 neuroimages, slides of tissue specimens, and illustrations, the book uniquely describes: Ø the societal roots of the problem(target organ toxicity, regulatory incompetence, and performativity) Ø the subtypes and essential causes of dementia Ø the patterns, prevalence, and causes of dementia associated with antidepressants, antipsychotics, anxiolytics, mood stabilizers, and stimulants and Ø the actions and reforms which patients, providers, and policy makers might immediately pursue, in an effort to mitigate the causes and consequences of this iatrogenic tragedy.

Emphasizing the relevance of recent findings to the differential diagnoses of a wide range of neurological conditions, this book offers an account of drug- induced neurological disorders. Specific chapters discuss epidemiology and clinical significance, pathomechanisms, encephalopathies, disorders of consciousness, neuropsychiatric disorders, headaches, seizures, movement disorders, cerebrovascular disorders, myopathies, diseases of the spine and spinal cord, cerebellar disorders, aseptic meningitis, benign intracranial hypertension, disorders of the automatic nervous system, sleep disorders, Eosinophilia Myalgia Syndrome, serotonin syndrome, Gillian-Barre syndrome, subacute myelo-optico-neuropathy, and pituitary disorders. Jain is a consultant in pharmaceutical medicine. Annotation copyrighted by Book News Inc., Portland, OR.

This timely book reviews the current status of drug treatments in dementia, both in practice and in research. It commences with a brief overview of the dementia syndrome and provides guidance in making a diagnosis. It then focuses on treatment of the cognitive function, psychological and behavioural symptoms and co-existing diseases. Chapters devoted to measuring the effects and cost-effectiveness of anti-dementia drugs are included.

Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury.

Among neurodegenerative diseases, those that lead to a state of dementia are the aim of several investigations. Dementia is a chronic disease the prevalence of which is increasing worldwide. The number of dementia patients in the world is approximately 50 million, and it is estimated that the number of patients will reach 131.5 million by 2050. This increase will be accompanied by a significant increase in medical expenditures and other expenses, especially for elderly patients. Therefore, the maintenance cost of dementia in the future is expected to be quite high. For this reason, several investigations aim, firstly, to describe the key mechanisms involved in the origin of dementia and, secondly, to establish preventive and therapeutic strategies in order to understand and mitigate this debilitating pathology. This volume of Frontiers in Clinical Drug Research - Dementia explores the current comorbidities that cause cognitive impairment and the current management alternatives for clinical cases of dementia. The reviews contributed in these volume will provide readers with a current perspective on the subject. The topics covered in this volume include: - Comorbidities inducing mild cognitive impairment - an evaluation of the risk caused by some pathological conditions - Tau-targeted therapy in Alzheimer's disease - history and current state - Emerging nanotherapeutic strategies in Alzheimer's disease - Implication of dehydroepiandrosterone on dementia related to oxidative stress - Polyphenol compounds as potential therapeutic agents in Alzheimer’s disease The volume is a timely update on dementia treatment for clinical physicians, neurologists, gerontologists, pharmaceutical and medicinal chemistry researchers, and physiologists.